Genomic Precision

 A SeraCare blog focused on precision medicine and advanced clinical diagnostics

What Is The Difference Between Quality Control Software Like iQ NGS And LIMS?

Posted by Lorn Davis on Apr 6, 2018 8:00:00 AM

SeraCare Life Sciences, in partnership with GenomeWeb, recently offered this exciting on-demand webinar: 

Read More

Topics: QC Challenges, assay performance, performance-based metrics, QC Management Software, Clinical NGS Assays, qc management

Developing a Rock-Solid Lung Cancer Assay

Posted by Yves Konigshofer on Mar 15, 2018 11:55:00 AM

Next-generation sequencing (NGS) allows deeper insights than ever before into the human genome and a host of diseases and conditions. So it makes sense that there is a worldwide movement to employ NGS in a growing number of applications. But as the saying goes, with great power comes great responsibility.



Read More

Topics: NGS reference materials, Clinical NGS Assays, reference materials, Lung Cancer, standard operating procedures

An Efficient and Ultrasensitive NGS Solution for Profiling ctDNA [Poster Talk Video]

Posted by Trevor Brown on Mar 5, 2018 8:28:14 AM

SeraCare Customer Poster Talk Video with Data Presented by Asuragen

Next-generation sequencing (NGS) of liquid biopsies offers a minimally invasive alternative to solid tissue biopsies and a more holistic profile of intra- and inter-tumoral heterogeneity for therapy selection and disease monitoring. 

Watch the video and download this free poster to learn:
Read More

Topics: ctDNA, NGS assays, liquid biopsy, next gen sequencing, NGS reference materials

CNVs and Tumor Profiling: New CNV Materials for Breast, Lung, and Brain Cancer

Posted by Dana Ruminski Lowe, Ph.D. on Feb 14, 2018 4:00:00 PM

Simply described, copy number variations (CNVs) are DNA segments present at a variable copy number in comparison to a normal genome. It was originally thought that a CNV consisted of a region of greater than 1 kilobases, however advances in technology have allowed for identification of CNVs as small as 50 basepairs1.

Read More

Topics: biosynthetic reference materials, Clinical NGS Assays, Copy Number Variations (CNVs), Lung Cancer, Brain Cancer, Breast Cancer, tumor profiling

Reliable Interpretation of NGS Data: New Poster Talk Video

Posted by Cynthia Hendrickson, CEO Directed Genomics on Feb 1, 2018 8:00:00 AM

The ability to rapidly and effectively evaluate the performance of customized next-generation sequencing (NGS) panels is critical to provide high-quality sequencing solutions to customers. New England Biolabs®, together with Directed Genomics®, is developing a new offering, NEBNext Direct® Custom Ready Panels, which will allow researchers to select from a large library of genes for which baits have been developed and optimized, thus enabling rapid deployment of customized target-enrichment panels. Directed Genomics has been collaborating with SeraCare Life Sciences in order to streamline the optimization and characterization of NEBNext Direct target enrichment panels. 

Read More

Topics: NGS, SeraSeq, NGS assays, Variant Allele Frequencies, highly-multiplexed reference material, NGS reference materials, AMP2017, reference materials

With so many options, how do you select the best NGS cancer assay?

Posted by Catherine Huang on Jan 11, 2018 12:10:00 PM

Clinical labs must constantly evolve their test offerings in order to support the most recent advances in clinical care. For next-generation sequencing (NGS) tumor profiling assays, there are often multiple commercially available kits with similar claims for gene content and sensitivity, as well as customized solutions. How can you quickly perform an effective evaluation of available assay systems to make a data-driven choice?

Read More

Topics: fusion RNA, next-generation sequencing, Clinical NGS Assays, reference materials, custom

How am I going to test my assay? Should I use patient samples or biosynthetic materials?

Posted by Dan Brudzewsky on Jan 4, 2018 4:32:00 PM

Assay development and optimization for clinical genetics is increasingly challenging. In an era of clinical genomics, new technologies and clinical utilities constantly call for newer and better performing assays. Having access to an abundant supply of relevant and reliable test material is critical for quick assay development and well-documented assay performance.

Read More

Topics: assay development, biosynthetic reference materials, NGS reference materials

AMP Reference Material Forum: Themes and Highlights

Posted by Catherine Huang on Dec 22, 2017 12:30:00 PM

On November 14, 2017, AMP hosted a forum to discuss genetic testing reference material availability and needs. The forum attracted attendees including EQA providers, developers in industry and government, as well as scientists from clinical laboratories. Topics for discussion included reference material use and needs for assay validation, quality control, and proficiency testing. Throughout the talks, a few themes emerged and were discussed by multiple speakers.

Read More

Topics: Clinical Genetic Testing, AMP2017, reference materials

Higher Quality for Better QC

Posted by Heather Buckley on Dec 15, 2017 4:03:00 PM

For over 30 years, we have dedicated ourselves to helping IVD developers and clinical laboratories ensure the quality of their assays. So when the opportunity arose to enhance our own quality standards, we jumped on it. 

Heather M. Buckley, VP, Quality & Regulatory Affairs

Read More

Topics: QMS, Quality Management Systems, customer requirements, ISO 13485

As to Myeloid Diseases, Make a Habit of Three Things

Use genetic information to treat, or at least to diagnose and to predict

Posted by Ram Santhanam on Dec 13, 2017 2:15:00 PM

Previously, we wrote about the unique capabilities that next-generation sequencing (NGS) offers the oncology clinic. NGS could mark the beginning of a shift away from “single-site” technologies such as FISH and PCR-based testing, in favor of comprehensive screening across many different targets at once.

Read More

Topics: next-generation sequencing, myeloid cancer reference materials, myeloid, Myeloid diseases, targeted therapies

 
 

Subscribe for Updates

Recent Posts

Categories

see all